While the COVID-19 pandemic and pharma’s efforts to counter it were the top pharma concerns in 2020, that wasn’t the only innovation within the specialty pharmacy arena. AIS Health spoke with a variety of industry experts on various trends over the past year.
What were some of the most notable developments within the specialty pharmacy industry in 2020, and why?
David Lassen, Pharm.D., chief clinical officer at Prime Therapeutics LLC: “There were many approvals for rare conditions that previously had limited or no treatment options. These include:
“Two new agents, Enspryng and Uplizna, to treat neuromyelitis optica spectrum disorder (NMOSD). These agents will compete with Soliris and off-label Rituxan and at a lower cost compared to Soliris.